# Gilead Sciences (GILD) — News

GILD · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/gild/news

## Recent headlines

- [Monkeypox stocks rose in intraday trading, with VRAX up 6.67%, GILD gaining 2.75% and VTRS rising 2.12%.](https://www.ainvest.com/news/monkeypox-stocks-rose-intraday-trading-vrax-6-67-gild-gaining-2-75-vtrs-rising-2-12-2610-84) — AInvest Wire, Oct 15, 2026
- [Monkeypox stocks rose in regular trading, with TNXP up 6.8%, GILD gaining 2.5% and VTRS rising 1.9%.](https://www.ainvest.com/news/monkeypox-stocks-rose-regular-trading-tnxp-6-8-gild-gaining-2-5-vtrs-rising-1-9-2610-64) — AInvest Wire, Oct 14, 2026
  On October 14, 2026, shares of companies associated with monkeypox treatments and vaccines rose in regular trading. Tonix Pharmaceuticals Holding Corp (TNXP) gained 6.8%, while Gilead Sciences (GILD) rose 2.5%, and Verrica Pharmaceuticals (VTRS) increased by 1.9%. The uptick in stock prices…
- [Vir Biotechnology shares rise 1.7% on up to $1.9 bln licensing deal with Gilead](https://www.ainvest.com/news/vir-biotechnology-shares-rise-1-7-1-9-bln-licensing-deal-gilead-2610) — AInvest Wire, Oct 14, 2026
  Vir Biotechnology, Inc. (NASDAQ: VIR) shares rose 1.7% following the announcement of a multi-program collaboration and licensing agreement with Gilead Sciences, Inc. (GILD), valued at up to $1.9 billion . The partnership focuses on the discovery and development of novel PRO-XTEN® dual-masked T-cell…
- [Vir Biotechnology shares rise 11.3% premarket on partnership with Gilead Sciences](https://www.ainvest.com/news/vir-biotechnology-shares-rise-11-3-premarket-partnership-gilead-sciences-2610) — AInvest Wire, Oct 14, 2026
  Vir Biotechnology, Inc. (NASDAQ: VIR) shares rose 11.3% in premarket trading following news of a new partnership with Gilead Sciences, a major player in antiviral therapies. The collaboration is expected to focus on advancing Vir’s pipeline of investigational treatments for infectious diseases,…
- [Vir Biotechnology - Gilead to purchase 1,765,486 Vir Bio shares at $14.16 per share for $25 mln - SEC filing](https://www.ainvest.com/news/vir-biotechnology-gilead-purchase-1-765-486-vir-bio-shares-14-16-share-25-mln-sec-filing-2610) — AInvest Wire, Oct 14, 2026

## Similar Stocks

- [VRTX](https://www.lighthorse.io/tickers/vrtx) — Vertex Pharmaceuticals Incorporated - Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [REGN](https://www.lighthorse.io/tickers/regn) — Regeneron Pharmaceuticals, Inc. - Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [LGND](https://www.lighthorse.io/tickers/lgnd) — Ligand Pharmaceuticals Incorporated - Common Stock
- [VIR](https://www.lighthorse.io/tickers/vir) — Vir Biotechnology, Inc. - Common Stock
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).